We have had a lot of conversations with quality directors, QA managers, and manufacturing quality leads over the past two years about AI in pharmaceutical quality control. After enough of them, a pattern becomes clear enough to describe with some confidence, even if individual conversations do not all line up perfectly with it.
What quality teams want from AI is not what they are usually being offered. Most AI tools marketed to pharmaceutical quality functions promise to replace human judgment in some significant way, or to produce outputs that the quality team can act on without substantial interpretation. What we hear, consistently, is that quality teams do not want this and will not trust it. What they want is different: better preparation, better visibility, and better consistency in the work that currently consumes time without requiring qualified judgment.
The preparation problem is the real problem
When quality professionals describe where AI could help them, the majority of what they describe is preparation work: assembling batch record review packages, pulling together deviation documentation before an investigation meeting, generating trend summaries that currently require hours of manual data aggregation, and keeping CAPA status current in a way that does not depend on someone manually updating a spreadsheet. These are tasks with well-defined inputs, rule-based outputs, and no quality judgment required in the execution.
The misalignment between what the market offers and what quality teams need is that most AI products are built around the judgment layer, not the preparation layer. The market assumption seems to be that qualified reviewers want to offload their quality decisions to an algorithm. The actual quality professionals we talk to consistently push back on this assumption with the same response: the judgment is not the bottleneck. The preparation is. And even if they wanted to offload judgment, they could not, because the regulatory accountability for quality decisions rests with qualified humans and they are not interested in compromising that accountability.
What they will not accept: black-box outputs
The second consistent theme is opacity. Quality teams will not act on outputs they cannot explain. This is not risk aversion or technological skepticism; it is a regulatory requirement. When an FDA investigator asks why a batch was released or a deviation was closed a certain way, the quality team needs to be able to show the basis for the decision. An AI output that says "approved" without an auditable record of what it examined and what rule it applied is not useful in a GMP environment regardless of how accurate it might be on average.
What quality teams want is explainability in the regulatory sense: they want to be able to point to the record, show the comparison that was made, and demonstrate that the output follows from the input according to a documented and validated rule. This is different from the machine learning sense of explainability, which is often about feature attribution in a statistical model. The GMP-compatible version is simpler: show exactly what you looked at and what rule you applied.
This requirement is achievable for the preparation and pattern-recognition tasks that are genuinely automatable. It is much harder to achieve for judgment tasks, which is part of why those tasks should not be automated in the first place.
The validation conversation is not optional
Every quality professional we have spoken with raises validation before any other implementation consideration. Before any question about features, pricing, or integration, the question is: what does the validation package look like? This is not bureaucratic caution; it is the correct starting question for any software system used in GMP manufacturing. A system that touches batch records, deviation investigations, or quality decisions is a computerized system under GxP regulations and must be validated before it is used for regulated purposes.
The quality teams we respect most ask vendors for the IQ/OQ/PQ documentation before they agree to a pilot. They want to see the validation master plan, the risk assessment, and evidence that the vendor has been through pharmaceutical manufacturing validations before. Vendors who are surprised by these questions have not built their product for this market. Vendors who can answer them immediately, with organized documentation, are demonstrating that their system was designed with GMP manufacturing in mind from the start.
Where current tools fall short
The most common failure mode we see in AI tools aimed at pharmaceutical quality is a mismatch between the tool's design assumptions and the actual workflow it is being asked to fit. Tools built for general document review are retrofitted to batch record review without accounting for the specific data structures, exception categories, and routing requirements that GMP batch records involve. Tools built for generic text classification are applied to deviation investigation text without accounting for the domain-specific language and the regulatory significance of root cause categorizations.
The result is tools that require significant customization by the quality team to produce outputs that are useful, which transfers the implementation burden from the vendor to the customer and often results in a system that is not maintainable as the manufacturing environment evolves. Quality teams that have been through this experience are appropriately skeptical of AI vendors who promise rapid deployment without substantive configuration. The configuration is where the product either works or does not work for the specific documentation environment.
A second failure mode is poor audit trail implementation. Systems that do not log every action the AI takes in an audit-trail-compatible format with timestamps and record linkages are not usable in a GMP environment, full stop. This is not a feature; it is a baseline requirement. Tools that treat audit trail as a secondary concern have not been designed for regulated environments.
What the bar actually looks like
From conversations with quality professionals who have implemented AI tools successfully, the pattern of success looks like this: a narrow initial scope focused on the highest-volume preparation tasks, a validation package that the quality team can execute with defined effort and a clear timeline, an audit trail that covers every system action with the specificity required for GMP documentation, and a vendor team that includes people with actual GMP manufacturing experience who understand why the requirements are what they are.
The narrow scope is important. The failure mode of starting with too much scope is well-documented in enterprise quality system implementations generally. A system that promises to automate the entire deviation investigation process, from intake to CAPA closure, is a system that is likely to fail at multiple points in the workflow and require months of remediation. A system that automates the intake and routing steps, does it well, and builds from there is more likely to deliver durable value.
Trust in AI-assisted quality control is built incrementally, through demonstrated performance on well-defined tasks with transparent outputs, not through marketing claims about accuracy rates. The quality teams that have built effective AI workflows in GMP environments built them the same way they build validation confidence: one verified performance test at a time.
See how Katalyze AI performs on your documentation
Talk to the team about your batch records and deviation history. We will show you a working demo configured to your product type.
Request a Demo
